Ftse Mib
38.714,52
0,63%
DAX
22.410,27
-0,05%
S&P 500
5.955,25
-0,47%
NASDAQ
19.026,39
-1,35%
Bitcoin
88.289,12
-0,39%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Redhill Biopharma Ltd (RDHL) Redhill Biopharma Ltd (RDHL) Notizie

Redhill Biopharma Ltd

RDHL
3,60
-1,22 (-25,31%)
26 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
25/2/202513:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/2/202513:00PRNUSRedHill Licenses RHB-102 for Commercialization Worldwide..
04/2/202513:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/2/202513:00PRNUSRedHill Announces Initiation of Phase 2 Study of Opaganib..
03/2/202522:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/2/202522:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
21/1/202513:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/1/202513:00PRNUSRedHill's Talicia® Adds 8 Million Lives With Coverage by..
10/12/202413:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/12/202413:00PRNUSRadioprotective Activity of RedHill's Opaganib for GI-ARS..
02/12/202413:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/12/202413:00PRNUSRedHill Biopharma Awarded Judgment of Approximately $8..
14/11/202418:22EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
28/10/202412:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/10/202412:00PRNUSRedHill Selected to Present Opaganib at Conference Organized..
22/10/202413:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/10/202413:00PRNUSRedHill Announces Collaboration with a Leading U.S. Academic..
15/10/202412:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/10/202413:00PRNUSRedHill Biopharma Secures U.S. Government Funding through..
01/10/202413:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/10/202413:00PRNUSRedHill and Medi-Cal Deal Maintains Talicia® Reimbursement..
30/9/202413:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/9/202413:00PRNUSRedHill Announces New U.S. Coronavirus Patent for Opaganib,..
18/9/202415:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/9/202415:13EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/9/202413:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/9/202413:00PRNUSRedHill's Talicia® Listed as First-Line Choice for H. pylori..
05/9/202414:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202413:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202413:00PRNUSRedHill Biopharma Regains Compliance with Nasdaq Minimum Bid..
03/9/202413:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/9/202413:00PRNUSNew Peer-Reviewed Publication of Opaganib Phase 2/3 Data..
29/8/202413:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/8/202413:00PRNUSRedHill Biopharma Announces First Half 2024 Business..
26/8/202413:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/8/202413:00PRNUSRedHill's Opaganib Granted Orphan Drug Designation by the..
21/8/202413:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/8/202413:00PRNUSTalicia® Launched in the United Arab Emirates
20/8/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
19/8/202413:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/8/202413:00PRNUSRedHill Announces Positive Obesity and Diabetes Results with..
16/8/202413:13EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/8/202413:00PRNUSRedHill Biopharma Announces Plan to Implement ADS Ratio..
13/8/202419:37EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
13/8/202414:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/8/202413:01EDGAR2Form F-3 - Registration statement by foreign private issuers
07/8/202415:51EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
06/8/202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/8/202413:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/8/202413:00PRNUSNewly Published Positive Phase 3 Data Demonstrates 64%..
Apertura: 5,55 Min: 3,01 Max: 5,75
Chiusura: 4,82

La tua Cronologia

NASDAQ
RDHL
Redhill Biopharma
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci